Brigitte Wildemann

List of Publications by Year
in descending order

95	8,748	53794 45	43889 91
papers	citations	h-index	g-index

98	98	98	7064
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, 280.	7.2	686
2	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14.	7.2	593
3	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 2014, 261, 1-16.	3.6	494
4	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nature Reviews Neurology, 2010, 6, 383-392.	10.1	384
5	Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. European Journal of Immunology, 2005, 35, 3343-3352.	2.9	380
6	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation, 2016, 13, 279.	7.2	351
7	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216.	5.3	315
8	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	2.5	286
9	Neuromyelitis optica. Nature Reviews Disease Primers, 2020, 6, 85.	30.5	232
10	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
11	Prevalence of Newly Generated Naive Regulatory T Cells (Treg) Is Critical for Treg Suppressive Function and Determines Treg Dysfunction in Multiple Sclerosis. Journal of Immunology, 2007, 179, 1322-1330.	0.8	219
12	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation, 2016, 13, 282.	7.2	217
13	Aquaporinâ€4 Antibodies (<scp>NMO</scp>â€<scp>IgG</scp>) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature. Brain Pathology, 2013, 23, 661-683.	4.1	214
14	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation, 2016, 13, 281.	7.2	202
15	The history of neuromyelitis optica. Journal of Neuroinflammation, 2013, 10, 8.	7.2	188
16	Diagnostic criteria for Susac syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1287-1295.	1.9	184
17	Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e504.	6.0	173
18	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.6	169

#	Article	IF	Citations
19	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
20	Thymic Export Function and T Cell Homeostasis in Patients with Relapsing Remitting Multiple Sclerosis. Journal of Immunology, 2003, 171, 432-437.	0.8	130
21	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	1.9	123
22	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	2.0	110
23	Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis. Journal of Neuroimmunology, 2009, 216, 113-117.	2.3	105
24	Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in â€˜pattern II multiple sclerosisâ€™ and brain biopsy findings in a MOG-IgG-positive case. Multiple Sclerosis Journal, 2016, 22, 1541-1549.	3.0	96
25	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	12.8	87
26	Interferon Betaâ€“Induced Restoration of Regulatory T-Cell Function in Multiple Sclerosis Is Prompted by an Increase in Newly Generated Naive Regulatory T Cells. Archives of Neurology, 2008, 65, 1434.	4.5	86
27	Intracerebral Human Regulatory T Cells: Analysis of CD4+CD25+FOXP3+ T Cells in Brain Lesions and Cerebrospinal Fluid of Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e17988.	2.5	85
28	Neurological autoimmune diseases following vaccinations against SARSâ€CoVâ€2: a case series. European Journal of Neurology, 2022, 29, 555-563.	3.3	85
29	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:ÂResults from 163 lumbar punctures in 100 adult patients. Journal of Neuroinflammation, 2020, 17, 261.	7.2	84
30	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	7.2	82
31	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 1189-1197.	3.0	70
32	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67
33	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686.	1.9	66
34	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	64
35	GABAB receptor antibodies in paraneoplastic cerebellar ataxia. Journal of Neuroimmunology, 2013, 256, 94-96.	2.3	62
36	T-cell homeostasis in pediatric multiple sclerosis. Neurology, 2013, 81, 784-792.	1.1	62

#	Article	IF	Citations
37	A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. Journal of Neuroinflammation, 2010, 7, 21.	7.2	60
38	B cells undergo unique compartmentalized redistribution in multiple sclerosis. Journal of Autoimmunity, 2011, 37, 289-299.	6.5	58
39	Immunopathogenesis of Neuromyelitis Optica. Advances in Immunology, 2014, 121, 213-242.	2.2	55
40	Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography. Annals of Neurology, 2017, 82, 676-685.	5.3	54
41	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
42	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e204.	6.0	53
43	Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis. Journal of Immunology, 2013, 190, 4965-4970.	0.8	52
44	Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. Journal of Neuroinflammation, 2014, 11, 206.	7.2	50
45	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology, 2015, 85, 610-618.	1.1	50
46	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841.	9.0	48
47	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialâ€"study protocol. BMJ Open, 2016, 6, e010956.	1.9	46
48	Cerebrospinal fluid proteomic profiling in nusinersenâ€treated patients with spinal muscular atrophy. Journal of Neurochemistry, 2020, 153, 650-661.	3.9	44
49	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. Journal of Neuroinflammation, 2020, 17, 262.	7.2	44
50	The interleukinâ€7 receptor Î± chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. European Journal of Immunology, 2011, 41, 845-853.	2.9	42
51	Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. Journal of Neuroinflammation, 2013, 10, 7.	7.2	42
52	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	41
53	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
54	Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. Journal of Neuroimmunology, 2014, 267, 102-104.	2.3	37

#	Article	IF	Citations
55	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e363.	6.0	37
56	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology, 2020, 94, e407-e418.	1.1	36
57	A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunology and Cell Biology, 2015, 93, 396-405.	2.3	34
58	Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study. European Journal of Neurology, 1999, 6, 531-538.	3.3	33
59	Prednisolone and azathioprine are effective in DPPX antibodyâ€“positive autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e86.	6.0	29
60	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Journal of the Neurological Sciences, 2017, 381, 240-244.	0.6	29
61	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. Pain, 2020, 161, 787-796.	4.2	29
62	Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology, 2017, 89, 207-209.	1.1	27
63	From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. Journal of Neuroimmunology, 2017, 309, 77-81.	2.3	27
64	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1521-1532.	3.0	25
65	Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis. Journal of Neuroimmunology, 2016, 294, 18-26.	2.3	24
66	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	3.6	24
67	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflammation, 2016, 13, 278.	7.2	23
68	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1007-1013.	1.9	22
69	Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Annals of Neurology, 2000, 47, 211-217.	5.3	21
70	MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. Acta Neuropathologica, 2021, 141, 127-131.	7.7	21
71	Sodium MRI in Multiple Sclerosis is Compatible with Intracellular Sodium Accumulation and Inflammation-Induced Hyper-Cellularity of Acute Brain Lesions. Scientific Reports, 2016, 6, 31269.	3.3	20
72	Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?. Multiple Sclerosis Journal, 2017, 23, 114-118.	3.0	20

#	Article	IF	Citations
73	Low intrathecal antibody production despite high seroprevalence of Epsteinâ€“Barr virus in multiple sclerosis: a review of the literature. Journal of Neurology, 2018, 265, 239-252.	3.6	20
74	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. Journal of Neurology, 2019, 266, 165-173.	3.6	20
75	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e480.	6.0	19
76	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. Journal of Neurology, 2017, 264, 341-349.	3.6	18
77	Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment. Frontiers in Immunology, 2019, 10, 1204.	4.8	18
78	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. Journal of Neurochemistry, 2021, 158, 522-538.	3.9	18
79	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Annals of Neurology, 2022, 91, 192-202.	5.3	17
80	Rapid distinction of acute demyelinating disorders and central nervous system lymphoma by molecular analysis of cerebrospinal fluid cells. Journal of Neurology, 2001, 248, 127-130.	3.6	15
81	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
82	The expanding range of autoimmune disorders of the nervous system. Lancet Neurology, The, 2013, 12, 22-24.	10.2	14
83	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain, 2021, 144, 3126-3141.	7.6	14
84	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibodyâ€“Associated Disease. Neurology, 2022, 98, .	1.1	14
85	Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis. Journal of Neuroimmunology, 2016, 301, 53-60.	2.3	11
86	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11
87	Pain, depression, and quality of life in adults with MOGâ€antibodyâ€“associated disease. European Journal of Neurology, 2021, 28, 1645-1658.	3.3	11
88	Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg. Journal of Neuroimmunology, 2015, 278, 60-68.	2.3	8
89	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devicesâ€”A Critical Appraisal. Cells, 2021, 10, 1232.	4.1	8
90	Neurologyâ€”the next 10 years. Nature Reviews Neurology, 2015, 11, 658-664.	10.1	7

#	Article	IF	Citations
91	Genetic determinants of the humoral immune response in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e827.	6.0	7
92	Transient MOG antibody seroconversion associated with immunomodulating therapy. Multiple Sclerosis and Related Disorders, 2020, 37, 101420.	2.0	4
93	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. PLoS ONE, 2016, 11, e0155322.	2.5	4
94	COVID-19-related severe MS exacerbation with life-threatening Takotsubo cardiomyopathy in a previously stable patient and interference of MS therapy with long-term immunity against SARS-CoV-2. Journal of Neurology, 2022, 269, 1138-1141.	3.6	3
95	Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis. Journal of Neurology, 2022, 269, 5420-5430.	3.6	2